| ²é¿´: 1269 | »Ø¸´: 0 | |||
bioonionгæ (СÓÐÃûÆø)
|
[½»Á÷]
EGFRÒÖÖÆ¼ÁCO-1686µÄÑо¿½øÕ¹
|
|
Ò»¡¢ EGFR¼ò½é EGFRÊÇÔ°©»ùÒòc-erbB1µÄ±í´ï²úÎÊÇ±íÆ¤Éú³¤Òò×ÓÊÜÌ壨HER£©¼Ò×å³ÉÔ±Ö®Ò»¡£¸Ã¼Ò×å°üÀ¨HER1£¨erbB1£¬EGFR£©¡¢HER2£¨erbB2£¬NEU£©¡¢HER3£¨erbB3£©¼°HER4£¨erbB4£©¡£HER¼Ò×åÔÚϸ°ûÉúÀí¹ý³ÌÖз¢»ÓÖØÒªµÄµ÷½Ú×÷ÓᣠEGFR¹ã·º·Ö²¼ÓÚ²¸È鶯ÎïÉÏÆ¤Ï¸°û¡¢³ÉÏËάϸ°û¡¢½ºÖÊϸ°û¡¢½ÇÖÊϸ°ûµÈϸ°û±íÃæ£¬EGFRÐźÅͨ·¶Ôϸ°ûµÄÉú³¤¡¢ÔöÖ³ºÍ·Ö»¯µÈÉúÀí¹ý³Ì·¢»ÓÖØÒªµÄ×÷Óá£EGFRµÈµ°°×ÀÒ°±Ëἤø¹¦ÄÜȱʧ»òÆäÏà¹ØÐźÅͨ·ÖйؼüÒò×ӵĻîÐÔ»òϸ°û¶¨Î»Òì³££¬¾ù»áÒýÆðÖ×Áö¡¢ÌÇÄò²¡¡¢ÃâÒßȱÏݼ°ÐÄѪ¹Ü¼²²¡µÄ·¢Éú¡£ ¶þ¡¢ ÐźÅͨ·ͼ Èý¡¢ÒÖÖÆ¼ÁCO-1686 Ò©Îï¼ò½é£º CO-1686 (AVL-301)ÊÇÒ»ÖÖ²»¿ÉÄæµÄ£¬Í»±äÑ¡ÔñÐÔµÄEGFRÒÖÖÆ¼Á£¬×÷ÓÃÓÚEGFRL858R/T790MºÍEGFRWT£¬ Ki·Ö±ðΪ21.5 nMºÍ303.3 nM¡£Phase 2¡£ ÌåÍâ»îÐÔÑо¿£º CO-1686 inhibits p-EGFR with IC50 ranging from 62 to 187 nM in the mutant EGFR¨Cexpressing cells, while inhibits EGFR phosphorylation with IC50 of > 2,000 nM in the three WT EGFR¨Cexpressing cells. CO-1686 selectively inhibits growth of NSCLC cells expressing mutant EGFR with GI50 ranging from 7 to 32 nM, and induces apoptosis. CO-1686¨Cresistant NSCLC cell lines exhibits signs of epithelial-mesenchymal transition and increased sensitivity to AKT inhibitors. ÌåÄÚ»îÐÔÑо¿£º CO-1686 causes dose-dependent and significant tumor growth inhibition in all EGFR-mutant models as well as human EGFRL858R- and EGFRL858R/T790M-expressing transgenic mice. |
» ²ÂÄãϲ»¶
0703»¯Ñ§Çóµ÷¼Á£¬¸÷λÀÏʦ¿´¿´ÎÒ£¡£¡£¡
ÒѾÓÐ3È˻ظ´
339Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
287Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ 070300 ѧ˶ 336·Ö Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085602 »¯¹¤×¨Ë¶ 338·Ö Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
0856£¬²ÄÁÏÓ뻯¹¤321·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤´óѧ²ÄÁÏÓ뻯¹¤ 264·Ö¸÷¿Æ¹ýAÇø¹ú¼ÒÏß
ÒѾÓÐ10È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
265Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
286Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
ÕÒµ½Ò»Ð©Ïà¹ØµÄ¾«»ªÌû×Ó£¬Ï£ÍûÓÐÓÃŶ~
2013ÉϰëÄêÉúÎïÒ½Ò©ÐÐÒµ¸ÅÀÀ£¨¹ÉƱ¡¢½»Òס¢ÐÂÒ©£©
ÒѾÓÐ8È˻ظ´
¿ÆÑдÓСľ³æ¿ªÊ¼£¬ÈËÈËΪÎÒ£¬ÎÒΪÈËÈË














»Ø¸´´ËÂ¥
µã»÷ÕâÀïËÑË÷¸ü¶àÏà¹Ø×ÊÔ´